Population genetics of venous thromboembolism

Maurizio Margaglione; Elvira Grandone

doi:10.1160/TH10-08-0510

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2011; 105(02): 221-231
DOI: 10.1160/TH10-08-0510

Review Article

Schattauer GmbH

Population genetics of venous thromboembolism

A narrative review

Authors

Maurizio Margaglione

¹Genetica Medica, Università di Foggia, Foggia, Italy

²Unita’ di Aterosclerosi e Trombosi, I.R.C.C.S. ″Casa Sollievo della Sofferenza″, S. Giovanni Rotondo, Foggia Italy
Elvira Grandone

²Unita’ di Aterosclerosi e Trombosi, I.R.C.C.S. ″Casa Sollievo della Sofferenza″, S. Giovanni Rotondo, Foggia Italy

Abstract

Summary

Results from epidemological studies are consistent with the hypothesis that disparities in venous thromboembolism (VTE) burden are attributable to differences in genetic structure among populations from different genetic backgrounds. To that end, recent genetic studies have demonstrated not only potential associations between certain alleles and VTE but also clear differences in the distribution of these alleles in patients stratified by ancestry. There are a number of notable clinical and pathophysiological questions that arise from these findings. First at all is defining the precise variant(s) that alter disease susceptibility. The comparatively lower rates of VTE recorded among Asians would imply that risk profile is devoid of many risk factors on comparison to Caucasian or African counterparts or that a putative protective factor is advocated in the former population. Identification of these variants provided specific insight into VTE disease in selected populations and also shed lights on the biology of the disease. The association observed between ancestry and VTE is likely to be multifactorial, possibly reflecting, in addition to genetic variation, also socioeconomic differences. Acknowledgment of this may provide useful information in biomedical contexts and help to identify individual risk factors for VTE.

Keywords

Epidemiological studies - familial thrombosis - gene mutations - thrombophilia - inherited coagulation disorders

Volltext

Referenzen

References
1 Kniffin WD. et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994; 154: 861-866.
2 Silverstein MD. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based, cohort study. Arch Intern Med 1998; 158: 585-593.
3 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
4 De Stefano V. et al. Inherited thrombophilia. Pathogenesis, clinical syndromes and management. Blood 1996; 87: 3531-3544.
5 Souto JC. et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J Hum Genet 2000; 67: 1452-1459.
6 Heit JA. et al. Familial segregation of venous thromboembolism. J Thromb Haemost 2004; 2: 731-736.
7 Larsen TB. et al. Major genetic susceptibility for venous thromboembolism in men: a study of Danish twins. Epidemiology 2003; 14: 328-332.
8 Patel RK. et al. Venous thromboembolism in the black population. Arch Intern Med 2004; 164: 1348-1349.
9 Schneider D. et al. The epidemiology of pulmonary embolism: racial contrasts in-incidence and in-hospital case fatality. J Natl Med Assoc 2006; 98: 1967-1972.
10 Aujesky D. et al. African American race was associated with an increased risk of complications following venous thromboembolism. J Clin Epid 2007; 60: 410-416.
11 Roberts LN. et al. Venous thromboembolism and ethnicity. Br J Haematol 2009; 146: 369-383.
12 White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 2009; 123 (Suppl. 04) S11-17.
13 White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (23) (Suppl. 01) 4-8.
14 Atichartakarn V. et al. Deep vein thrombosis after hip surgery among Thai. Arch Intern Med 1988; 148: 1349-1353.
15 Tso SC. et al. Deep vein thrombosis and changes in coagulation and fibrinolysis after gynaecological operations in Chinese: the effect of oral contraceptives and malignant disease. Br J Haematol 1980; 46: 603-612.
16 Duthie SJ, Ghosh A, Ma HK. Maternal mortality in Hong Kong 1961–1985. Br J Obstet Gynaecol 1989; 96: 4-8.
17 Geerts WH. et al. Prevention of venous thromboembolism. Chest 2001; 119 (Suppl. 01) 132S-175S.
18 Proctor MC, Greenfield LJ. Pulmonary embolism: diagnosis, incidence and implications. Cardiovasc Surg 1997; 5: 77-81.
19 White RH. et al. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128: 737-740.
20 Stein PD. et al. Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med 2004; 116: 435-442.
21 White RH. et al. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 2005; 93: 298-305.
22 Liu HS. et al. Venous thromboembolism in the Chinese population-experience in a regional hospital in Hong Kong. Hong Kong Med J 2002; 8: 400-405.
23 Cheuk BL. et al. Epidemiology of venous thromboembolism in a Chinese population. Br J Surg 2004; 91: 424-428.
24 Kumasaka N. et al. Incidence of pulmonary thromboembolism in Japan. Jpn Circ J 1999; 63: 439-441.
25 Sakuma M. et al. Venous thromboembolism: deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone. Circ J 2009; 73: 305-309.
26 Cogo A. et al. Acquired risk factors for deep-vein thrombosis in symptomatic out-patients. Arch Intern Med 1994; 154: 164-168.
27 Anderson Jr FA. et al. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992; 152: 1660-1664.
28 Chan LY. et al. Symptomatic venous thromboembolism in Chinese patients after gynecologic surgery: incidence and disease pattern. Acta Obstet Gynecol Scand 2002; 81: 343-346.
29 Angchaisuksiri P. et al. Risk factors of venous thromboembolism in thai patients. Int J Hematol 2007; 86: 397-402.
30 Guo H. et al. Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience. Am J Hematol 2010; 85: 499-501.
31 Koh Y. et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Ann Hematol 2010; 89: 201-206.
32 Piovella F. et al. Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost 2005; 3: 2664-2670.
33 Heit JA. et al. Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol 2010; 85: 467-471.
34 Sotunmbi PT. et al. Prevalence of venous thromboembolism at post-mortem in an African population: a cause for concern. Afr J Med Sci 2006; 35: 345-348.
35 Crittenden LB. An interpretation of familial aggregation based on multiple genetic and environmental factors. Ann NY Acad Sci 1961; 91: 769-780.
36 Falconer DS. The inheritance of liability to certain diseases estimated from the incidence among relatives. Ann Hum Genet 1965; 29: 51-76.
37 Smith C. Recurrence risks for multifactorial inheritance. Am J Hum Genet 1971; 23: 578-588.
38 Den Heijer M. et al. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3: 292-299.
39 Virchow R. Phlogose und Thrombose im Gefäßsystem. Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt, Germany: Staatsdruckerei; 1856
40 Briggs JB. Recurrent phlebitis of obscure origin. John Hopkins Hosp Bull 1905; 16: 228-233.
41 Jordan FLJ, Nandorff A. The familial tendency in thrombo-embolic disease. Acta Med Scand 1956; 156: 267-275.
42 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530.
43 Egeberg O. Inherited fibrinogen abnormality causing thrombophilia. Thromb Diath Haemorrh 1967; 17: 176-187.
44 Griffin JH. et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373.
45 Comp PC. et al. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-2088.
46 Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001; 109: 369-384.
47 Lane DA. et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76: 651-662.
48 Linnemann B. et al. Hereditary and acquired thrombophilia in patients with upper extremity deep-vein thrombosis. Results from the MAISTHRO registry. Thromb Haemost 2008; 100: 440-446.
49 Dentali F. et al. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. Thromb Haemost 2008; 99: 675-682.
50 Baglin T. Management of Thrombophilia: Who to Screen?. Pathophysiol Haemost Thromb 2003/2004 33: 401-404.
51 Dallapiccola B. et al. A nationwide genetic testing survey in Italy, year 2007. Genet Test Mol Biomarkers 2010; 14: 17-22.
52 Picard V. et al. Antithrombin Phe229Leu: a new homozygous variant leading to spontaneous antithrombin polymerization in vivo associated with severe childhood thrombosis. Blood 2003; 102: 919-925.
53 Seligsohn U. et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 1984; 310: 559-562.
54 Chen TY. et al. Incidence of thrombophilia detected in southern Taiwanese patients with venous thrombosis. Ann Hematol 2003; 82: 114-117.
55 Shen MC. et al. Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan. Thromb Res 2000; 99: 447-452.
56 Ho CH. et al. Causes of venous thrombosis in fifty Chinese patients. Am J Hematol 2000; 63: 74-78.
57 Shen MC. et al. High prevalence of antithrombin III, protein C and protein S deficiency, but no factor V Leiden mutation in venous thrombophilic Chinese patients in Taiwan. Thromb Res 1997; 87: 377-385.
58 Suehisa E. et al. Frequency of natural coagulation inhibitor (antithrombin III, protein C and protein S) deficiencies in Japanese patients with spontaneous deep vein thrombosis. Blood Coagul Fibrinolysis 2001; 12: 95-99.
59 Kinoshita S. et al. Protein C and protein S gene mutations in Japanese deep vein thrombosis patients. Clin Biochem 2005; 38: 908-915.
60 Akkawat B, Rojnuckarin P. Protein S deficiency is common in a healthy Thai population. J Med Assoc Thai 2005; 88 (Suppl. 04) S249-254.
61 Wang ZY. Recent advances on thrombosis and haemostasis in Asian Pacific region: report of the Fourth Asian Pacific Congress on Thrombosis and Haemostasis: Conference report. Chin Med J 2006; 119: 2022-2024.
62 Jerrard-Dunne P. et al. Ethnic differences in markers of thrombophilia: implications for the investigation of ischemic stroke in multiethnic populations: the South London Ethnicity and Stroke Study. Stroke 2003; 34: 1821-1826.
63 Folsom AR. et al. Distributions of hemostatic variables in blacks and whites: population reference values from the Atherosclerosis Risk in Communities (ARIC) Study. Ethn Dis 1992; 2: 35-46.
64 Patel RK. et al. Risk factors for venous thrombosis in the black population. Thromb Haemost 2003; 90: 835-838.
65 Dahlbäck B. et al. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
66 Bertina RM. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
67 Rees DC. The population genetics of factor V Leiden (Arg506Gln). Br J Haematol 1996; 95: 579-586.
68 Pepe G. et al. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost 1997; 77: 329-331.
69 Rees DC. et al. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134.
70 De Stefano V. et al. Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost 1998; 24: 367-379.
71 Takamiya O. et al. APC-resistance and Mnl1 genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost 1995; 74: 996.
72 Ridker PM. et al. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. J Am Med Assoc 1997; 277: 1305-1307.
73 Jun ZJ. et al. Prevalence of factor V Leiden and prothrombin G20210A mutations in Chinese patients with deep venous thrombosis and pulmonary embolism. Clin Lab Haematol 2006; 28: 111-116.
74 Zivelin A. et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997; 89: 397-402.
75 Poort SR. et al. A common genetic variation in the 3 translated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
76 Emmerich J. et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3204 controls: Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86: 809-816.
77 Danckwardt S, Gehring NH, Neu-Yilik G. et al. The prothrombin 3‘end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. Blood 2004; 104: 428-435.
78 Rosendaal FR, Doggen CJ, Zivelin A. et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-708.
79 de Maat MP, Bladbjerg EM, Johansen LG. et al. Absence of prothrombin mutation in Inuit (Greenland Eskimos). Thromb Haemost 1998; 79: 882.
80 Miyata T. et al. The prothrombin gene G20210A mutation is not found among Japanese patients with deep vein thrombosis and healthy individuals. Blood Coagul Fibrinolysis 1998; 9: 451-452.
81 Dilley A. et al. Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. J Lab Clin Med 1998; 132: 452-455.
82 Rees DC, Chapman NH, Webster MT. et al. Born to clot: the European burden. Br J Haematol 1999; 105: 564-566.
83 Ho CH. Prevalence of prothrombin 20210A allele and methylenetetrahydrofolate reductase C677T genetic mutations in the Chinese population. Ann Hematol 2000; 79: 239-242.
84 Zivelin A. et al. Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years ago. Blood 2006; 107: 4666-4668.
85 Lucotte G, Mercier G. Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis 2001; 27: 362-367.
86 Nichols WC. et al. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 1996; 88: 1183-1187.
87 Lindqvist PG. et al. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss-a possible evolutionary selection mechanism. Thromb Haemost 1998; 79: 69-73.
88 Corral J. et al. Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. Blood 2001; 97: 2979-2982.
89 Donahue BS. et al. Factor V Leiden protects against blood loss and transfusion after cardiac surgery. Circulation 2003; 107: 1003-1008.
90 Kerlin BA. et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003; 102: 3085-3092.
91 Xue Y. et al. Population differentiation as an indicator of recent positive selection in humans: an empirical evaluation. Genetics 2009; 183: 1065-1077.
92 Dowling NF. et al. The epidemiology of venous thromboembolism in Caucasians and African-Americans: the GATE Study. J Thromb Haemost 2003; 1: 80-87.
93 Jick H. et al. Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1969; 1: 539-542.
94 Talbot S. et al. A19 A29 B, and O blood-groups, Lewis blood-groups, and serum triglyceride and cholesterol concentrations in patients with venous thromboembolic disease. Lancet 1972; 1: 1152-1154.
95 Allan TM. ABO blood groups and age groups in surgical venous thromboembolism. Atherosclerosis 1976; 23: 141-142.
96 Jick H, Porter J. Thrombophlebitis of the lower extremities and ABO blood type. Arch Intern Med 1978; 138: 1566-1567.
97 Robinson WM, Roisenberg I. Venous thromboembolism and ABO blood groups in a Brazilian population. Hum Genet 1980; 55: 129-131.
98 Wautrecht JC, Galle C, Motte S. et al. The role of ABO blood groups in the incidence of deep vein thrombosis. Thromb Haemost 1998; 79: 688-689.
99 Schleef M, Strobel E, Dick A. et al. Relationship between ABO and secretor geno-type with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br J Haematol 2005; 128: 100-107.
100 Mercier B. et al. Phenotypic but not allelic ABO blood group association with risk of venous thrombosis. Thromb Haemost 2005; 93: 388-389.
101 Tirado I. et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost 2005; 93: 468-474.
102 Larsen TB. et al. ABO blood groups and risk of venous thromboembolism during pregnancy and the puerperium. A population-based, nested case-control study. J Thromb Haemost 2005; 3: 300-304.
103 Morelli VM. et al. ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost 2005; 3: 183-185.
104 Ohira T. et al. ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). J Thromb Haemost 2007; 5: 1455-1461.
105 Wu O. et al. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 62-69.
106 Calafell F. et al. Evolutionary dynamics of the human ABO gene. Hum Genet 2008; 124: 123-135.
107 Swerdlow DL. et al. Severe life-threatening cholera associated with blood group O in Peru: implications for the Latin American epidemic. J Infect Dis 1994; 170: 468-472.
108 Black RE. et al. Association between O blood group and occurrence and severity of diarrhoea due to Escherichia coli. Trans R Soc Trop Med Hyg 1987; 81: 120-123.
109 Fry AE. et al. Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falciparum malaria. Hum Mol Genet 2008; 17: 567-576.
110 Garratty G. et al. Retrovirus Epidemiology Donor Study. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Trans-fusion 2004; 44: 703-706.
111 Matsui T. et al. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem 1992; 267: 8723-8731.
112 O’Donnell JS. et al. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood 2005; 106: 1988-1991.
113 Sarode R. et al. Role of A and B blood group antigens in the expression of adhesive activity of von Willebrand factor. Br J Haematol 2000; 109: 857-864.
114 Sodetz JM. et al. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem 1977; 252: 5538-5546.
115 Orstavik KH. et al. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985; 37: 89-101.
116 Miller CH. et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 2003; 1: 2191-2197.
117 Conlan MG. et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70: 380-385.
118 Green D. et al. Hemostatic factors in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb 1994; 14: 686-693.
119 Sukhu K. et al. Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease. Clin Lab Haematol 2003; 25: 247-249.
120 Koster T. et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 1995; 345: 152-155.
121 Ashley-Koch A. et al. Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review. Am J Epidemiol 2000; 151: 839-845.
122 Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 2003; 115: 721-728.
123 Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002; 99: 36-43.
124 Ashcroft MT, Desai P. Mortality and morbidity in Jamaican adults with sickle cell trait and with normal hemoglobin followed up for 12 years. Lancet 1976; 2: 784.
125 World Health Organization.. Sickle cell anemia. Report by the secretariat. 59th World Health Assembly. April 2, 2006.
126 Lorey FW. et al. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. Genet Epidemiol 1996; 13: 501-512.
127 Heller P. et al. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. N Engl J Med 1979; 300: 1001-1005.
128 Feldenzer JA. et al. Superior sagittal sinus thrombosis with infarction in sickle cell trait. Stroke 1987; 18: 656-660.
129 Humphries JE, Wheby MS. Case report: sickle cell trait and recurrent deep venous thrombosis. Am J Med Sci 1992; 303: 112-114.
130 Austin H. et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 2007; 110: 908-912.
131 Austin H. et al. Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. Am J Obstet Gynecol 2009; 200: 620.e1-3.
132 Westerman MP. et al. Coagulation changes in individuals with sickle cell trait. Am J Hematol 2002; 69: 89-94.
133 Franck PF. et al. Uncoupling of the membrane skeleton from the lipid bilayer: the cause of accelerated phospholipid flip-flop leading to an enhanced procoagulant activity of sickle cells. J Clin Invest 1985; 75: 183-190.
134 Blumenfeld N. et al. Transmembrane mobility of phospholipids in sickle erythrocytes: Effect of deoxygenation on diffusion and asymmetry. Blood 1991; 77: 849-854.
135 Tait JF, Gibson D. Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. J Lab Clin Med 1994; 123: 741-748.
136 Helley D. et al. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and β-thalassemia. Thromb Haemost 1996; 76: 322-327.
137 Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121-1132.
138 Bergeron MF. et al. Erythrocyte sickling during exercise and thermal stress. Clin J Sport Med 2004; 14: 354-356.
139 Gill FM. et al. Clinical events in the first decade in a cohort of infants with sickle cell disease: Cooperative Study of Sickle Cell Disease. Blood 1995; 86: 776-783.
140 Ballas SK. et al. Clinical, hematological, and biochemical features of Hb SCdis-ease. Am J Hematol 1982; 13: 37-51.
141 Gillis S. et al. Pulmonary thromboembolism in thalassemia intermedia patients. Haematologica 1999; 84: 959-960.
142 Zalloua PA. et al. Incidence of thromboembolic events in Lebanese thalassemia intermedia patients. Thromb Haemost 2003; 89: 767-768.
143 Taher A. et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006; 96: 488-491.
144 Cappellini MD. et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000; 111: 467-473.
145 Sonakul D, Fucharoen S. Pulmonary thromboembolism in thalassemic patients. Southeast Asian J Tropic Med Pub Hlth 1992; 23 (Suppl. 02) 25-28.
146 Angchaisuksiri P. et al. Hemostatic and thrombotic markers in patients with hemoglobin E/beta-thalassemia disease. Am J Hematol 2007; 82: 1001-1004.
147 Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. Ann NY Acad Sci 1998; 850: 251-259.
148 Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bulletin of the World Health Organization 2001; 79: 704-712.
149 Bateson P. et al. Developmental plasticity and human health. Nature 2004; 430: 419-421.
150 O’Rourke DH, Raff JA. The human genetic history of the Americas: the final frontier. Curr Biol 2010; 20: R202-207.
151 Kayser M. et al. Y chromosome STR haplotypes and the genetic structure of U.S. populations of African, European, and Hispanic ancestry. Genome Res 2003; 13: 624-634.
152 Bryc K. et al. Colloquium paper: genome-wide patterns of population structure and admixture among Hispanic/Latino populations. Proc Natl Acad Sci USA 2010; 107 (Suppl. 02) 8954-8961.
153 Bamshad M. et al. Deconstructing the relationship between genetics and race. Nat Rev Genet 2004; 5: 598-609.
154 Witherspoon DJ. et al. Genetic similarities within and between human populations. Genetics 2007; 176: 351-359.
155 Schwartz RS. Racial profiling in medical research. N Engl J Med 2001; 344: 1392-1393.
156 Stein PD. et al. Pulmonary Thromboembolism in American Indians and Alaskan Natives. Arch Intern Med 2004; 164: 1804-1806.
157 Klatsky AL. et al. Risk of Pulmonary Embolism and/or Deep Venous Thrombosis in Asian-Americans. Am J Cardiol 2000; 85: 1334-1337.
158 Nossent JC, Egelie NC. Incidence and course of symptomatic deep venous thrombosis of the lower extremities in a black Caribbean population. Thromb Haemost 1993; 70: 576-578.
159 Hooper WC. et al. Venous thromboembolism hospitalizations among American Indians and Alaska Natives. Thromb Res 2002; 108: 273-278.
160 Silverstein MD. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based, cohort study. Arch Intern Med 1998; 158: 585-593.
161 Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Thromb Haemost 2000; 83: 657-660.
162 Nordström M. et al. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-160.
163 Hansson PO. et al. Deep vein thrombosis and pulmonary embolism in the general population. ‘The Study of Men Born in 1913‘. Arch Intern Med 1997; 157: 1665-1670.
164 Chafa O. et al. The relative frequency of inherited inhibitor deficiency among 93 young patients with thrombophilia in Algeria. Blood Coagul Fibrinolysis 1993; 4: 639-640.
165 Ruiz-Argüelles GJ. et al. Primary thrombophilia in Mexico: a prospective study. Am J Hematol 1999; 60: 1-5.
166 Nicholls EM. et al. Blood Group and Serum Protein Differences in Some Central Australian Aborigines. Am J Hum Genet 1965; 17: 293-307.
167 Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86: 480-487.
168 Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 2001; 79: 1-15.
169 Bain BJ. Neonatal/newborn haemoglobinopathy screening in Europe and Africa. J Clin Pathol 2009; 62: 53-56.